Flerie AB Logo

Flerie AB

FLERIE | ST

Overview

Corporate Details

ISIN(s):
SE0022447348
LEI:
54930047C4A74IBXR037
Country:
Sweden
Address:
BERZELIUS VÄG 13, 171 65 Solna
Sector:
Health Care
Industry:
Pharmaceuticals

Description

Flerie AB is a pharmaceutical company focusing on immunological diseases with great medical needs for new treatment options. The portfolio of the company includes Immuno-Oncology, metabolic diseases, and biologics development and manufacturing organizations. Flerie was established in 2011 by Thomas Eldered, who co-founded and built one of the global top five drug manufacturers, Recipharm. Dr Carl-Johan Spak, now Senior Advisor, and Thomas laid the foundation for Flerie’s evergreen strategy and oversaw the early investments. Flerie sold Cormorant Pharmaceuticals to BMS in 2016 and Cobra Biologics to Cognate Bioservices in early 2020 – this enabled further investments. In 2018, Dr Ted Fjällman, then chief executive of one of the portfolio companies, joined as Venture Partner, later Partner and CEO of Flerie.

Social Media

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-06-04 08:00
Net Asset Value(s)
SUBSTANSVÄRDE – 31 maj 2025
Swedish 43.5 KB
2025-06-04 08:00
Net Asset Value(s)
NET ASSET VALUE – 31 May 2025
English 43.0 KB
2025-05-23 07:30
Takeover Announcement Report
Flerie Invest AB lämnar ett kontant budpliktsbud till aktieägarna Nanologica AB…
Swedish 62.8 KB
2025-05-23 07:30
Takeover Announcement Report
Flerie Invest AB announces a mandatory cash offer to the shareholders of Nanolo…
English 61.6 KB
2025-05-14 14:00
Regulatory News Service
The General Meetings of Flerie and Toleranzia respectively have approved the me…
English 52.1 KB
2025-05-14 14:00
Regulatory News Service
Bolagsstämmorna i Flerie respektive Toleranzia har godkänt fusionsplanen och bo…
Swedish 44.7 KB
2025-05-14 12:30
Regulatory News Service
Stämmokommuniké från årsstämma i Flerie AB (publ) den 14 maj 2025
Swedish 35.6 KB
2025-05-14 12:30
Regulatory News Service
Bulletin from the Annual General Meeting of Flerie AB (publ) on 14 May 2025
English 35.9 KB
2025-05-07 08:00
Regulatory News Service
SUBSTANSVÄRDE – 30 april 2025
Swedish 43.5 KB
2025-05-07 08:00
Regulatory News Service
NET ASSET VALUE – 30 April 2025
English 42.9 KB
2025-04-30 18:30
Regulatory News Service
Flerie erhåller FDI-godkännande avseende fusionen med Toleranzia
Swedish 46.1 KB
2025-04-30 18:30
Regulatory News Service
Flerie receives FDI-approval for the merger with Toleranzia
English 52.8 KB
2025-04-25 19:15
Takeover Announcement Report
Flerie has increased its holding in Nanologica, whereby an obligation to make a…
English 31.8 KB
2025-04-25 19:15
Transaction in Own Shares
Flerie har ökat sitt innehav i Nanologica varigenom budplikt uppkommer
Swedish 30.7 KB
2025-03-25 10:30
Inside Information Statement
Flerie and Toleranzia have agreed on a merger plan to take Toleranzia private
English 79.9 KB

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
ABIVAX Logo ABIVAX France ABVX
Addex Therapeutics Ltd Logo Addex Therapeutics Ltd Switzerland ADXN
AegirBio AB Logo AegirBio AB Sweden AEGIR
AGRONOMICS LIMITED Logo AGRONOMICS LIMITED Isle of Man ANIC
AIREA PLC Logo AIREA PLC United Kingdom AIEA
Alkaloid AD Logo Alkaloid AD North Macedonia ALK
Alma Yesodot Ltd. Israel KVSR
Antibiotice S.A. Logo Antibiotice S.A. Romania ATB
Aran Research & Development (1982) Ltd. Logo Aran Research & Development (1982) Ltd. Israel ARAN
Asarina Pharma AB Logo Asarina Pharma AB Sweden ASAP